Wolfgang Miesbach: From CD20 to CD38 – A New Dimension in ITTP Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Paul Coppo, published in JTH, adding։
“From CD20 to CD38: a new dimension in iTTP therapy.
Preemptive rituximab guided by ADAMTS13 has transformed iTTP follow-up, but a subset of patients still relapse or remain refractory and need alternative strategies.
In a recent RPTH commentary, Paul Coppo highlights daratumumab in 5 heavily pretreated iTTP patients (8 episodes), with an 87.5% overall response rate, rapid ADAMTS13 recovery in about 2–4 weeks, and a median ADAMTS13 relapse-free survival of 32 months, without reported infectious complications.
By targeting CD38 on long-lived plasma cells, daratumumab depletes persistent anti–ADAMTS13–producing cells that are not eliminated by CD20-directed therapies, offering a mechanistically distinct salvage approach in multiresistant iTTP.”
Title: Daratumumab in relapse-refractory immune-mediated thrombotic thrombocytopenic purpura: additional evidence for its efficacy
Author: Paul Coppo
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 31, 2026, 05:35Does LDL Cholesterol Influence VTE Risk? – Ordo Fraterna Fibonacci
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients
-
Aug 31, 2026, 04:28Reza Hafidz Irawan։ Automated Antibody Titration With Erytra Eflexis
-
Aug 31, 2026, 04:17Safa Chenganath: Stenosis vs Thrombosis – Hemodialysis Vascular Access
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session